BRCA1 and cancer: Because it is not an essentialprotein under normal circumstances, EXO1 inhibition would effectivelytarget the defective replication-associated DSB repair systems foundin many cancer types, particularly those that are hormone-dependent,already possess mutations in HR proteins like BRCA1/2, or have acquiredresistance to other DSB response-targeting agents such as PARPi.